787 Stock Overview
Operates as a contract research organization worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 787 from our risk checks.
Selvita S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł11.70 |
| 52 Week High | zł16.46 |
| 52 Week Low | zł11.32 |
| Beta | 0.021 |
| 11 Month Change | -16.55% |
| 3 Month Change | -16.67% |
| 1 Year Change | -10.69% |
| 33 Year Change | -30.61% |
| 5 Year Change | n/a |
| Change since IPO | -5.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 787 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.5% | -7.0% | -1.5% |
| 1Y | -10.7% | 1.3% | 7.9% |
Return vs Industry: 787 underperformed the German Life Sciences industry which returned 2.8% over the past year.
Return vs Market: 787 underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| 787 volatility | |
|---|---|
| 787 Average Weekly Movement | 5.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 787 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 787's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 387 | Boguslaw Sieczkowski | selvita.com |
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, autoimmune/immunology, neurology, respiratory, and other.
Selvita S.A. Fundamentals Summary
| 787 fundamental statistics | |
|---|---|
| Market cap | €227.48m |
| Earnings (TTM) | €10.98m |
| Revenue (TTM) | €76.22m |
20.7x
P/E Ratio3.0x
P/S RatioIs 787 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 787 income statement (TTM) | |
|---|---|
| Revenue | zł329.02m |
| Cost of Revenue | zł70.13m |
| Gross Profit | zł258.89m |
| Other Expenses | zł211.49m |
| Earnings | zł47.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 78.69% |
| Net Profit Margin | 14.41% |
| Debt/Equity Ratio | 39.8% |
How did 787 perform over the long term?
See historical performance and comparison